导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.06% | 1691/4773 |
| 近一周 | -1.04% | 1567/5465 |
| 近一月 | -3.62% | 2692/5421 |
| 近一季 | -8.84% | 3427/5231 |
| 近半年 | -5.37% | 3015/4920 |
| 近一年 | 6.71% | 1565/4394 |
| 近两年 | 67.89% | 1050/2954 |
| 近三年 | 35.02% | 910/2253 |
| 成立以来 | 21.70% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.80% 1181/4961 |
17.33% 1472/5312 |
- - |
- - |
| 2025 | 28.89% 1443/4813 |
1.86% 1532/3635 |
1.71% 2216/4076 |
23.63% 1526/4524 |
0.63% 1885/4813 |
| 2024 | 6.68% 1733/3463 |
-2.48% 1366/2808 |
-5.08% 1638/3014 |
15.37% 1731/3129 |
-0.12% 1324/3463 |
| 2023 | -6.70% 871/2656 |
7.16% 596/2280 |
-4.31% 1134/2385 |
-4.73% 1212/2515 |
-4.49% 1059/2655 |
| 2022 | -18.30% 687/2207 |
-13.40% 751/1919 |
2.94% 1236/2016 |
-10.26% 374/2113 |
2.12% 1033/2208 |
| 2021 | 14.97% 315/1822 |
-1.74% 536/1255 |
9.38% 555/1330 |
4.34% 363/1466 |
2.51% 574/1822 |
| 2020 | 26.65% 600/1250 |
-3.57% 309/1028 |
15.81% 472/1067 |
9.35% 655/1164 |
3.71% 892/1184 |
| 2019 | 25.52% 598/1092 |
30.34% 252/739 |
-9.13% 632/788 |
0.29% 535/850 |
5.66% 693/918 |
| 2018 | -29.44% 452/834 |
- - |
-12.64% 402/631 |
-6.52% 407/660 |
-11.99% 390/682 |
| 2017 | 1.11% 456/714 |
- - |
- - |
- - |
- - |
| 2016 | -16.87% 388/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 景顺长城中证500ETF联接 VS. 长安沪深300非周期A(740101) |